ArticleScientific reports2025
Community acceptance of Ivermectin mass drug administration for malaria in Southern Thailand.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Thailand's goal to eliminate malaria by 2030 faces significant challenges, in part due to inadequate vector control measures. Innovative strategies, such as mass drug administration (MDA) of ivermectin, have shown promise in improving vector control efforts. This study aims to assess the factors influencing the acceptance of ivermectin MDA among residents in southern Thailand. In 2022, a cross-sectional study was conducted in three districts of Surat Thani Province, southern Thailand, where an ivermectin MDA program was planned. Quantitative data were collected through structured surveys administered to randomly selected household heads using a standardized questionnaire. Descriptive statistics and multiple logistic regression models were employed to identify factors associated with the reported acceptance of ivermectin MDA. A total of 391 participants were surveyed, with the majority (96.4%) expressing acceptance of the planned ivermectin MDA. Forest-related workers (aOR: 4.2, 95% CI: 1.1-16.1) and those who believed malaria could be eliminated from their villages (aOR: 9.1, 95% CI: 2.8-29.9) were more likely to exhibit higher levels of acceptance. However, according to programmatic records, only 59.0% of the 3,137 eligible individuals completed all three rounds of ivermectin MDA. Key barriers to participation included absence from the village for unspecified reasons and reluctance to take the drug, particularly in later rounds. There was a noticeable gap between reported acceptance and actual participation in the ivermectin MDA. Targeted efforts to engage forest-related workers are crucial to maintain high participation rates. Strengthening community engagement by emphasizing the risks and benefits of ivermectin, outlining safety measures, and raising awareness about malaria prevention and control are crucial for improving MDA uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.